Dr. Petros Grivas shares what data he's most looking forward to discussing at the second Uromigos: Live & Unplugged event. Dr. de Kouchkovsky highlights survival and response rates after ICIs and EV for patients with squamous histology. Dr. de Kouchkovsky explains studying the impact of squamous histology on clinical outcomes in mUC after ICIs or EV. Anke Richters, PhD, discusses how not reporting primary end point changes in clinical trials can lead to issues. Dr. Satkunasivam shares the inspiration for combining sasanlimab with BCG in patients with high-risk, BCG-naïve NMIBC. The FDA may allow the temporary use of drugs from overseas to alleviate the ongoing cisplatin and carboplatin shortages. Dr. Scott Eggener provides an overview of the advancements in and patient perspectives on Grade Group 1 prostate cancer. Dr. Prasad provides overviews of ATLAS and ENVISION and opines on whether UGN-102 is a practice-ready alternative to TURBT. Drs. Marshall, Reimers, and Dorff discuss toxicities from single-agent and combination-based HR inhibitors. Drs. Marshall, Reimers, and Dorff discuss PARP inhibitor strategies for BRCA-mutated patients throughout the care continuum. Dr. Kommalapati shares her thoughts on the association between tumor-informed MRD and clinical outcomes for MIBC. Dr. Satkunasivam details the RAD VACCINE MIBC trial, an evaluation of the efficacy and safety of neoadjuvant sasanlimab. Dr. Satkunasivam explains the momentum for an IO-plus-radiation strategy in MIBC, as well as the potential of sasanlimab. Drs. Shilpa Gupta and Vadim Koshkin continue on the EV-103 trial with reference to outcomes and toxicities in cohort K. Drs. Shilpa Gupta and Vadim Koshkin discuss the EV-103 trial and data, including long-term results for cohort A. Drs. Rini and Plimack discuss the "negative" findings from CONTACT-03. Drs. Rini and Plimack discuss "impressive" non-clear cell RCC data. Drs. Rini and Plimack discuss the CLEAR and KEYNOTE-426 RCC updates. Tanya Jindal expands upon the UNITE study findings relative to biomarkers of response for SG and EV for advanced UC. Dr. Calais describes a novel radiotracer and explains how the recent data on this radiotracer further support its use.